Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results Reported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile

#ELDN Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation Eledon Pharmaceuticals (NASDAQ: ELDN) announced that the FDA granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation on March 10, 2026. Tegoprubart previously held orphan designations for pancreatic islet transplantation and ALS.The company cites kidney transplant clinical studies and preclinical liver data supporting further evaluation, and anticipates an investigator-sponsored clinical trial to begin later in 2026.

#ELDN Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

www.stocktitan.net/news/ELDN/eledon-pharmac...

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX (Nasdaq: NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (Nasdaq: ELDN) to evaluate combination strategies pairing NewcelX's lead stem-cell-derived islet program, NCEL-101, with Eledon's anti-CD40L antibody tegoprubart (AT-1501).The collaboration leverages clinical experience from >100 transplant patients treated with tegoprubart and aims to support durable, immune-protected islet replacement, potentially clarifying regulatory pathways and accelerating NCEL-101 development toward pivotal milestones.

#ELDN #NCEL NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

www.stocktitan.net/news/ELDN/newcel-x-annou...

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium Eledon Pharmaceuticals (Nasdaq: ELDN) will present 24-month follow-up data from eight patients in a Phase 1b long-term extension evaluating tegoprubart in de novo kidney transplant recipients at the American Society of Transplant Surgeons Winter Symposium, January 23–25, 2026.Key results from the eight-patient cohort: no biopsy-proven acute rejection, no graft loss, no deaths, no new-onset diabetes mellitus, and no de novo donor-specific antibody formation during the study period. Mean eGFR rose from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Poster #62 will be presented January 23, 2026; the poster will be posted in the company's Investors section after the presentation.

#ELDN Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook Eledon Pharmaceuticals (Nasdaq: ELDN) summarized 2025 progress and provided a 2026 outlook centered on tegoprubart development across kidney allotransplantation, islet transplantation and xenotransplantation. Key 2025 results: Phase 2 BESTOW showed a mean eGFR of 69 mL/min/1.73 m² (n=51) at 12 months and demonstrated non-inferiority versus tacrolimus on an efficacy-failure composite (22.2% vs. 17.2% using a 20% non-inferiority margin). Investigator-led islet transplants (UChicago) reported insulin independence in the first six patients. Tegoprubart was used in four pig-to-human xenotransplants (three at MGH). The company completed a $57.5 million financing, expected to fund operations into 2Q 2027. Anticipated 2026 milestones include FDA guidance on Phase 3 design and multiple long-term data readouts.

#ELDN Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q3 2025 results and business highlights on Nov 14, 2025. Key points: Phase 2 BESTOW data showed tegoprubart with a favorable safety profile and an eGFR of approximately 69 mL/min/1.73m2 at 12 months in the treatment arm (n=51), supporting plans to advance to Phase 3 after regulator discussions. The company completed an underwritten public offering on Nov 13, 2025, raising $57.5 million gross (net ≈ $53.6M) to fund transplantation programs. Cash and short-term investments were $93.4 million as of Sept 30, 2025. Anticipated 2026 milestones include FDA guidance and initiation of a Phase 3 kidney transplant trial.

#ELDN Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and (ii) in lieu of common stock to

#ELDN Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants Eledon Pharmaceuticals (NASDAQ: ELDN) announced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock.The company will grant underwriters a 30-day option to buy up to 15% additional shares (overallotment). The offering is subject to market and other conditions and may not be completed. Leerink Partners and Cantor are joint book-running managers.Eledon intends to use net proceeds to support continued clinical development of product candidates, advance pipeline programs, and for general corporate purposes. The offering is made under a Form S-3 registration (File No. 333-282260) declared effective October 2, 2024, with a preliminary prospectus supplement to be filed with the SEC.

#ELDN Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ELDN/eledon-pharmac...

Leading Indicators, Monday November 10, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Mon Nov 10th - #WTBA #UVSP #SLRC #RRBI #PAHC #NRC #NBBK #MATD #LAND #KATS #IFRX #GAIN #FFIC #ELDN #DERM #CABA #BEAT #VSTS #AROW #VSTS #UVE #SMHI #PDS #ORN #MATV #LB #KBDC #GOOS #FSLY #EFXT - More: crystalequityresearch.com/leading-indi... - #smallcap

JUST IN: ( NASDAQ: #ELDN ) Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology's Kidney Week 2025 Annual Meeting

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #RANI 25.1x
2. #ELDN 23.6x
3. #LUNR 9.6x
4. #PLNT 7.7x
5. #UPXI 7.5x

#OptionFlow #OptionsTrading #Trading

Eledon Posts Narrower Loss in Q2 | The Motley Fool

#ELDN #91d438ae-0842-4752-9e91-1de004e685ab #data-news

Origin | Interest | Match

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results Eledon Pharmaceuticals (NASDAQ: ELDN) reported Q2 2025 financial results and clinical progress for its lead drug tegoprubart. The company highlighted positive Phase 1b data in kidney transplant patients, showing a mean 12-month eGFR of approximately 68 mL/min/1.73 m2, significantly better than the historical standard of care (~53 mL/min/1.73 m2).Key developments include successful treatment of six islet cell transplant recipients at UChicago Medicine, with the first three achieving insulin independence, and a third patient receiving tegoprubart in kidney xenotransplantation at MGH. The company reported $107.6 million in cash as of June 30, 2025, expected to fund operations through 2026, and anticipates Phase 2 BESTOW trial results in kidney transplantation by November 2025.

#ELDN Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation Eledon Pharmaceuticals (NASDAQ: ELDN) presented updated data from its ongoing Phase 1b trial of tegoprubart for kidney transplant rejection prevention. The trial showed promising results with patients maintaining an average 12-month eGFR of 68 mL/min/1.73 m², significantly higher than the historical standard of care average of 53 mL/min/1.73 m².The study enrolled 32 patients, with preliminary iBox data suggesting tegoprubart may achieve over 96% predicted 5-year allograft survival rate. The drug demonstrated strong safety profile with no deaths, graft loss, drug-related tremor, or new-onset diabetes. While six rejection episodes occurred, all were successfully treated, with patients remaining on tegoprubart showing superior kidney function recovery compared to those who switched to standard care.The company expects topline results from its Phase 2 BESTOW trial in November 2025.

#ELDN Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

www.stocktitan.net/news/ELDN/eledon-present...

Elden Ring Nightreign: 7 Tips to Beat the First Boss, the Nightlord Gladius The Tricephalos boss is the real proving grounds of Elden Ring Nightreign, and many of the game's features are hidden behind beating it.

Elden Ring Nightreign: 7 Tips to Beat the First Boss, the Nightlord Gladius The Tricephalos boss is the real proving grounds of Elden Ring Nightreign, and many of the game's features are hidden behind beating it.. @cosmicmeta.io #Eldn

https://u2m.io/MhrPCvHO

Eledon Advances Revolutionary Transplant Drug: Q4 Phase 2 Results Coming as Cash Hits $124.9M Latest trial data shows promise for tegoprubart in kidney transplants. Strong $124.9M cash position funds operations through 2026. Get Q4 milestone updates.

#ELDN Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results Eledon Pharmaceuticals (NASDAQ: ELDN) reported its Q4 and full year 2024 results, highlighting significant advances in organ transplantation. Their lead drug tegoprubart was successfully used in two landmark procedures: a genetically modified pig kidney transplant at Massachusetts General Hospital and islet transplants for type 1 diabetes patients at UChicago Medicine.The company strengthened its financial position through an $85 million oversubscribed offering, extending their cash runway to end of 2026. As of December 31, 2024, cash and investments stood at $140.2 million.For Q4 2024, R&D expenses were $17.9 million and G&A expenses were $6.8 million, with a net loss of $44.6 million ($0.64 per share). Full year 2024 resulted in a net loss of $36.2 million ($0.75 per share). The company expects topline results from their Phase 2 BESTOW trial in kidney transplantation by Q4 2025.

#ELDN Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/ELDN/eledon-pharmac...

Eledon's Tegoprubart Achieves Major Breakthrough in Kidney Transplant Trials, Secures $135M Funding Eledon reports early completion of Phase 2 BESTOW trial, breakthrough in xenotransplantation, and positive diabetes treatment data. Funding secured through 2026.

#ELDN Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

www.stocktitan.net/news/ELDN/eledon-pharmac...

Breaking News: ( NASDAQ: #ELDN ) Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #ELDN ) Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

#StockMarket #News